Sage Therapeutics, Inc.
DelistedCIK 1597553fmd_05FG22X1AQDJSZMTZ7DE8E85RHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2025, 50 periods
Latest annual · FY2024
Millions- Total revenues
- 41
- Operating income
- (432)
- Net income
- (401)
- Free cash flow
- (267)
Latest quarter · Q2 FY2025
Millions- Total revenues
- 32
- Operating income
- (54)
- Net income
- (50)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +87.0%
- Revenue, 5 yearsFY2019 to FY2024
- +43.1%
- Net income, 5 yearsFY2019 to FY2024
- n/m
Sage Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $41.2 million | $86.5 million | -52.3% | 10-K 2025-02-11 · proof |
| Operating income | -$432.4 million | -$579.8 million | 10-K 2025-02-11 · proof | |
| Net income | -$400.7 million | -$541.5 million | 10-K 2025-02-11 · proof | |
| Cash from operating activities | -$267.2 million | -$540.6 million | 10-K 2025-02-11 · proof | |
| Free cash flow | -$267.2 million | -$541.1 million | 10-K 2025-02-11 · proof | |
| Total assets | $547.2 million | $882.3 million | -38% | 10-K 2025-02-11 · proof |
| Total liabilities | $82.1 million | $82.7 million | -0.7% | 10-K 2025-02-11 · proof |
| Cash and cash equivalents | $81 million | $71 million | +14.1% | 10-K 2025-02-11 · proof |
- What was Sage Therapeutics, Inc.'s revenue in fiscal 2024?
- Sage Therapeutics, Inc. reported revenue of $41.2 million for fiscal 2024 (the year ended Dec 31, 2024), against $86.5 million the year before (-52.3%). Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What was Sage Therapeutics, Inc.'s operating income in fiscal 2024?
- Sage Therapeutics, Inc. reported operating income of -$432.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$579.8 million the year before. Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What was Sage Therapeutics, Inc.'s net income in fiscal 2024?
- Sage Therapeutics, Inc. reported net income of -$400.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$541.5 million the year before. Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What was Sage Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Sage Therapeutics, Inc. reported cash from operating activities of -$267.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$540.6 million the year before. Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What was Sage Therapeutics, Inc.'s free cash flow in fiscal 2024?
- Sage Therapeutics, Inc. reported free cash flow of -$267.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$541.1 million the year before. Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What are Sage Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Sage Therapeutics, Inc. reported total assets of $547.2 million, against $882.3 million a year earlier (-38%). Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What are Sage Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Sage Therapeutics, Inc. reported total liabilities of $82.1 million, against $82.7 million a year earlier (-0.7%). Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
- What are Sage Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Sage Therapeutics, Inc. reported cash and cash equivalents of $81 million, against $71 million a year earlier (+14.1%). Source: the 10-K filed with the SEC on Feb 11, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1597553&period_type=annual&limit=5"Information only, not investment advice.